Skip to Content

MAP Drugnews

CN ON: Doctors Call For No Tax On Medicinal Marijuana

MAP Drugnews - Top Stories - Sat, 12/16/2017 - 01:00
The Record, 12 Dec 2017 - Ottawa must withdraw its plan to charge tax on medicinal marijuana or risk having an adverse effect on patients, a group of more than 50 doctors warned Monday as the federal government hashed out a pot-tax revenue-sharing agreement with the provinces and territories. The doctors, who describe themselves as a group of physicians who routinely prescribe marijuana to their patients, say applying a sales or excise tax to medicinal pot would impose a financial barrier for those who use the drug to manage their symptoms, compared to patients who take other medication.
Categories: News Feeds

CN NS: Editorial: Planting The Seed Of Opportunism

MAP Drugnews - Top Stories - Sat, 12/16/2017 - 01:00
Truro Daily News, 12 Dec 2017 - It's funny how quickly a criminal enterprise can turn into a legitimate business opportunity. As a federal Conservative politician, even as late as 2015, Julian Fantino was opposed to the legalization of marijuana. In 2004, he even compared weed to murder in an interview with the Toronto Sun, saying, "I guess we can legalize murder too and then we won't have a murder case. We can't go that way." Now, he's partnered with former RCMP deputy commissioner Raf Souccar to open a medical marijuana business, Aleafia Total Health Network.
Categories: News Feeds

CN ON: Manitoba Pushes For Whole Pot Pie

MAP Drugnews - Top Stories - Sat, 12/16/2017 - 01:00
Winnipeg Free Press, 11 Dec 2017 - OTTAWA - Manitoba will push the federal government to transfer all of the sin taxes collected from recreational marijuana into provincial coffers, the Free Press has learned. "This is a federal policy, with a federal timeline, with provincial obligations and responsibilities," provincial Finance Minister Cameron Friesen said.
Categories: News Feeds

CN ON: 'I Am Tired Of Having To Go To Funerals'

MAP Drugnews - Top Stories - Sat, 12/16/2017 - 01:00
Toronto Star, 12 Dec 2017 - Fighting back tears, Olympia Lynn Trypis stood in the rotunda of city hall and begged for better services for drug users, to save her life and the lives of her friends. "In the last two years I've lost three of my really close friends and I am tired of having to go to funerals and not celebrating more birthdays. These people were beautiful souls," said Trypis, 22, speaking to a crowd who had marched to city hall in memory of people lost to drug overdoses, or contaminated drugs.
Categories: News Feeds

CN ON: Backers Give Injection Site Search Shot In Arm

MAP Drugnews - Top Stories - Sat, 12/16/2017 - 01:00
London Free Press, 11 Dec 2017 - It'll be months before London finds out if it gets the go-ahead and funding for supervised drug injection sites, but it appears key players already are walking in unison to support the sites, but restrict where they can locate. The area's medical officer of health, a key city planner and an advocate for the downtrodden all express some confidence there will be suitable sites sufficiently far from schools and other places frequented by children.
Categories: News Feeds

CN MB: Homegrown Pot Ban 'Silly'

MAP Drugnews - Top Stories - Sat, 12/16/2017 - 01:00
Winnipeg Sun, 11 Dec 2017 - Consumer advocacy group concerned marijuana treated differently than booze A consumer choice advocacy group has condemned the Manitoba government's plan to ban homegrown marijuana when it becomes legal in the country next year.
Categories: News Feeds

Barely illegal: A tour of LA's highbrow cannabis scene - The Independent

Google - Cannabis - Fri, 12/15/2017 - 17:02

The Independent

Barely illegal: A tour of LA's highbrow cannabis scene
The Independent
She is explaining that consuming marijuana allows a woman to awaken her “yoni”, a Sanskrit term for vagina favoured by Hollywood bohemians. “Everybody stand up!” she shouts. The crowd, all women, seated on pillows on the floor, leap to their feet ...

Categories: News Feeds

North Dakota Cannabis Legalization Petition OK'd for Circulation - Leafly

Google - Cannabis - Fri, 12/15/2017 - 16:54


North Dakota Cannabis Legalization Petition OK'd for Circulation
North Dakota Cannabis Legalization Petition OK'd for Circulation. The Associated Press. December 15, 2017. (DenisTangneyJr/iStock). BISMARCK, N.D. (AP) — A proposal to legalize recreational marijuana in North Dakota will go the voters if supporters ...
ND attorney general approves marijuana petition formatKFYR-TV

all 4 news articles »
Categories: News Feeds

The 3 States Best Positioned to Legalize Marijuana in 2018

Alternet - Fri, 12/15/2017 - 15:39
Click here for reuse options! Next year should see more legal marijuana states and also the first state to legalize pot at the statehouse.

Election Day 2016 was a big day for marijuana. Voters in California, Maine, Massachusetts, and Nevada all supported successful legalization initiatives, doubling the number of states to have done so since 2012 and more than quadrupling the percentage of the national population that now lives in legal marijuana states.

Marijuana momentum was high, national polling kept seeing support go up and up, and 2017 was expected to see even more states jump on the weed bandwagon. That didn't happen.

There are two main reasons 2017 was a dud for pot legalization: First, it's an off-off-year election year, and there were no legalization initiatives on the ballot. Second, it's tough to get a marijuana legalization bill through a state legislature and signed by a governor. In fact, it's so tough it hasn't happened yet.

But that doesn't mean it isn't going to happen next year. Several states where legislative efforts were stalled last year are poised to get over the top in the coming legislative sessions, and it looks like a legalization initiative will be on the ballot in at least one state—maybe more.

There are other states where legalization is getting serious attention, such as Connecticut, Delaware and Rhode Island, but they all have governors who are not interested in going down that path, and that means a successful legalization bill faces the higher hurdle of winning with veto-proof majorities. Similarly, there are other states where legalization initiatives are afoot, such as Arizona, North Dakota and Ohio, but none of those have even completed signature gathering, and all would face an uphill fight. Still, we could be pleasantly surprised.

Barring pleasant surprises, here are the three states that have the best shot at legalizing pot in 2018.

1. Michigan

Michigan voters shouldn't have to wait on the state legislature to act because it looks very likely that a legalization initiative will qualify for the ballot next year. The Michigan Coalition to Regulate Marijuana Like Alcohol has already completed a petition campaign and handed in more than 365,000 raw signatures last month for its legalization initiative. It hasn't officially qualified for the ballot yet, but it only needs 250,000 valid voter signatures to do so, meaning it has a rather substantial cushion.

If the measure makes the ballot, it should win. There is the little matter of actually campaigning to pass the initiative, which should require a million or two dollars for TV ad buys and other get-out-the-vote efforts, but with the Marijuana Policy Project on board and some deep-pocketed local interests as well, the money should be there.

The voters already are there: Polling has shown majority support for legalization for several years now, always trending up, and most recently hitting 58% in a May Marketing Resource Group poll.

2. New Jersey

Outgoing Gov. Chris Christie (R) was a huge obstacle to passage of marijuana legalization, but he's on his way out the door, and his replacement, Gov.-Elect Phil Murphy (D), has vowed to legalize marijuana within 100 days of taking office next month.

Legislators anticipating Christie's exit filed legalization bills earlier this year, Senate Bill 3195 and companion measure Assembly Bill 4872. State Senate President Stephen Sweeney (D) has also made promises, vowing to pass the bill within the first three months of the Murphy administration, and hearings are set for both houses between January and March.

But it's not a done deal. There is some opposition in the legislature, and marijuana legalization foes will certainly mobilize to defeat it at the statehouse. It will also be the first time the legislature seriously considers legalization. Still, legalization has some key political players backing it. Other legislators might want to listen to their constituents: A September Quinnipiac poll had support for legalization at 59%.

3. Vermont

A marijuana legalization bill actually passed the legislature last year, a national first, only to be vetoed by Gov. Phil Scott (R) over concerns around drugged driving and youth use. Legislators then amended the bill to assuage Scott's concerns and managed to get the amended bill through the Senate, only to see House Republicans refuse to let it come to a vote during the truncated summer session.

But that measure, House Bill 511, will still be alive in the second year of the biennial session, and Gov. Scott has said he is still willing to sign the bill. House Speaker Mitzi Johnson (D) is also on board, and the rump Republicans won't be able to block action next year.

Johnson said she will be ready for a vote in early January and expects the bill to pass then. Vermont would then become the first state to free the weed through the legislative process. 


Click here for reuse options!  Related Stories
Categories: News Feeds

Denver Shuts Down 26 Legal Cannabis Businesses, Makes Arrests - Leafly

Google - Cannabis - Fri, 12/15/2017 - 15:27


Denver Shuts Down 26 Legal Cannabis Businesses, Makes Arrests
DENVER (AP) — Denver authorities shut down 26 legal marijuana businesses Thursday and arrested 12 people suspected of illegal distribution of cannabis after a yearlong criminal investigation. Potential charges relate to marijuana sales exceeding ...
Police raid eight Sweet Leaf Marijuana Center locations in Denver and AuroraThe Cannabist

all 20 news articles »
Categories: News Feeds

'Foolish not to': Manitoba First Nations want in on legal pot sales -

Google - Cannabis - Fri, 12/15/2017 - 14:33

CTV News

'Foolish not to': Manitoba First Nations want in on legal pot sales
Manitoba First Nation makes major investment in pot company · What is a cannabis information specialist and how can I become one? Polar bear capital of the world debating sale of legalized marijuana · Manitoba lone holdout on federal pot tax plan · Pot ...
3 Manitoba First Nations enter partnership with cannabis companyCTV News

all 2 news articles »
Categories: News Feeds

First Nations apply to sell marijuana at Winnipeg locations - Winnipeg Free Press

Google - Cannabis - Fri, 12/15/2017 - 14:16

Winnipeg Free Press

First Nations apply to sell marijuana at Winnipeg locations
Winnipeg Free Press
They have a partnership agreement with National Access Cannabis, a chain of medical cannabis access clinics with plans to open recreational marijuana dispensaries after legalization on July 1. The chain is responding to the Manitoba government's ...

Categories: News Feeds

Medical marijuana production facility planned for Corner Brook ... - The Western Star

Google - Cannabis - Fri, 12/15/2017 - 14:09

The Western Star

Medical marijuana production facility planned for Corner Brook ...
The Western Star
If everything goes according to plan Corner Brook will soon see a medical marijuana production facility. BeeHigh Vital Elements Inc. announced its plan to become a licensed producer of medical marijuana in a press release Friday. Rita Hall, an.

and more »
Categories: News Feeds

9 Ways Scientists Are Exploring the Body’s Relationship with Marijuana

Alternet - Fri, 12/15/2017 - 12:12
Better living through endocannabinoid science.

In recent years, cannabis has been at the center of one of the most important developments in modern science, which has significantly advanced our understanding of health and disease.

Research on marijuana’s effects led directly to the discovery of a major biochemical signaling system in the human body – the endocannabinoid system – which plays a pivotal role in regulating a wide range of physiological processes that affect our mood, our blood pressure, our bone density, our metabolism, our intestinal fortitude, our energy level, how we experience pain, stress, hunger, and much more.

“By using a plant that has been around for thousands of years, we discovered a new physiological system of immense importance,” says Israeli scientist Raphael Mechoulam. “We wouldn’t have been able to get there if we had not looked at the plant.”

Described by Mechoulam as “a medicinal treasure trove,” cannabis contains more than 100 unique biologically active compounds known as “cannabinoids,” including tetrahydrocannabinol (THC) and cannabidiol (CBD). THC causes the high that cannabis is famous for, CBD does not; both have important therapeutic attributes.

In addition to phytocannabinoids produced by the plant, there are endogenous cannabinoids – marijuana-like molecules – that occur naturally in the human brain and body. And there are also synthetic cannabinoids created by pharmaceutical researchers, who are developing new medicines that target the endocannabinoid system for therapeutic benefit.

Some of these novel synthetic compounds activate the same cannabinoid receptors – CB1 and CB2 – in the brain and body that respond pharmacologically to THC and other cannabis components.1

Medical scientists are also experimenting with synthetic drugs designed to improve “endocannabinoid tone” without binding directly to cannabinoid receptors.

Here are nine strategies that scientists are currently pursuing in an effort to harness the healing potential of the endocannabinoid system:

1. Single-molecule plant cannabinoids

Dronabinol, marketed in pill form as Marinol, is a single-molecule THC extract combined with sesame oil. It got fast-tracked for approval by the Food and Drug Administration in 1985 in response to rising patient demand for medical marijuana.

Other THC preparations are also on the FDA’s radar, including Syndros, a liquid THC drug produced by Insys. But patented single-molecule THC is a poor substitute for whole plant cannabis.

Even though it is highly psychoactive and potentially dysphoric, pharmaceutical THC is legally accessible in all 50 states as a prescription medication.

Cannabidiol, unlike pure THC, is not yet legal in all 50 states. But CBD will soon become a legal pharmaceutical, as the FDA is poised to approve Epidiolex, a botanically derived anti-seizure medication produced by GW Pharmaceuticals. Epidiolex is pure CBD with a dash of cannabidivarin (CBDV), a “minor” cannabinoid that also has potent anti-epileptic properties.

Along with the imminent advent of pharmaceutical CBD, several R&D firms have begun to harvest single-molecule cannabinoids, such as CBDV, from a yeast substrate. As this biotechnology improves, drug developers and pharmacists will have access to numerous single-molecule cannabis compounds.

2. Synthetic cannabinoid analogs

Scientists have created synthetic analogs of plant cannabinoids for research purposes and for commercial sale and distribution. Nabilone, a synthetic THC analog, was developed by Eli Lilly and Co. as a treatment for chemotherapy-induced nausea and vomiting.

Marketed under the trade name Cesamet, this synthetic cannabinoid is used as an adjunct therapy for chronic pain management in Canada and other countries. Clinical trials of Nabilone have indicated some effectiveness for fibromyalgia, Parkinson’s, PTSD-related nightmares, irritable bowel disease, and multiple sclerosis.

Researchers are using various synthetic analogs to investigate the biochemical pathways and molecular mechanisms of the endocannabinoid system. Some of these compounds (such as WIN55,212-2 and CP55,940) bind to both cannabinoid receptors – CB1 and CB2 – much like THC. Other experimental drugs target only one type of cannabinoid receptor and not the other. 2

A cannabinoid agonist binds to a cell receptor and causes it to initiate a signaling cascade that modulates various physiological processes and protects neurons against toxic insults. A cannabinoid antagonist binds to a cell receptor and prevents it from signaling.

3. Synthetic cannabinoid antagonists

Cannabinoid CB1 receptors, which mediate the psychoactive effects of THC, are concentrated in the brain and central nervous system. When THC binds to CB1, it can make a person feel stoned – and hungry. The “munchies,” scientists confirmed, are linked to stimulation of CB1 receptors in areas of the brain that regulate hunger and satiety. If activated, CB1 receptors induce appetite; if blocked, they reduce it.

“SR141716,” a synthetic CB1 antagonist developed by the French pharmaceutical giant Sanofi-Aventis, was initially utilized as a research tool: By blocking CB1 and monitoring which functions were altered, scientists advanced their understanding of the endocannabinoid system.

Sanofi strategists believed they had invented the perfect diet pill, and they promoted SR141716 as an appetite suppressant in Europe. But the diet drug, sold as “Rimonabant,” proved to be too blunt an instrument. Before long, the synthetic CB1 antagonist was pulled from circulation because of dangerous side effects – high blood pressure, nausea, vomiting, anxiety, mood swings, depression, headaches, seizures, sleep disorders, and a heightened risk of suicide.

If nothing else, the CB1 antagonist debacle provided vivid evidence that a well-functioning endocannabinoid system is essential for good health.3

4. Peripherally restricted CB1 agonists

Cannabinoid CB1 receptors, the most prevalent protein receptors in the human brain, influence many neurological functions, including marijuana’s mood-altering effects. CB1 receptors are also expressed in the enteric nervous system (the gut), the liver, kidneys, heart and other peripheral organs.

Stimulating CB1 receptors can deliver significant therapeutic benefits, but THC’s psychoactivity limits its medical utility, according to Big Pharma catechism, which defines the CB1-mediated marijuana “high” as an adverse side effect that drug designers should avoid if they hope to win regulatory approval of their patented synthetic novelties.

So pharmaceutical researchers have created peripherally-restricted CB1 agonists (such as AZ11713908) that only activate CB1 receptors outside the central nervous system, but don’t cross the blood-brain barrier.

A peripherally restricted CB1 agonist won’t cause side effects such as disconcerting dysphoria or useless euphoria. But such a compound has never been approved for therapeutic use by the FDA.

5. Selective CB2 agonists

Scientists have been hot on the trail of another type of synthetic cannabinoid – a “selective CB2 agonist” – that will bypass the brain while acting on the peripheral nervous system, where CB2 receptors are concentrated. CB2 receptors regulate immune function, pain perception, and inflammation.

Tinkering with synthetic compounds (such as HU308 and JWH 133) that selectively stimulate CB2receptors raises the prospect of healing without the high because CB2 receptors are localized primarily outside the brain and thus do not induce psychoactivity.

Cannabinoid researchers have their eyes on the ultimate prize, the pharmaceutical Holy Grail – a non-addictive painkiller bereft of adverse side effects. Animal experiments focusing on the CB2 receptor initially showed promise.

Thus far, however, drug companies have not been able to synthesize clinically effective CB2-selective compounds, though not for lack of trying. “If drug discovery is a sea, then CB2 is a rock that is surrounded by shipwrecked-projects,” remarked Italian scientist Giovanni Appendino.

6. Water-soluble cannabinoids

In their natural form, plant cannabinoids and endocannabinoids are oily, hydrophobic substances that don’t dissolve in water. But these lipid molecules can be structurally altered so that they become water soluble without diminishing their therapeutic attributes.

Scientists have developed several ways of synthesizing water-compatible derivatives of THCand other cannabinoids that are more bioavailable and thus potentially more potent than their oily, naturally-occurring counterparts.

The first water-soluble version of THC was created in 1972. Subsequent research found that water-friendly cannabinoid derivatives can lower intraocular pressure in rabbits. A water-soluble cannabinoid ester, “O-1057,” exhibited stronger analgesic properties than THC in preclinical experimentation.

Internet retailers are claiming to sell water-soluble CBD formulated as a nanoemulsion. Pure CBD delivered via nanotechnology is supposed to provide exceptionally high bioavailability and remedial effect compared to a hydrophobic CBD oil extract.

But a CBD isolate typically requires a much higher dose for therapeutic efficacy than a whole plant CBD-rich concentrate – and this factor may cancel out the alleged advantages of nanoemulsified single-molecule CBD.

7. Allosteric cannabinoid receptor modulators

Because direct, full-on stimulation of cannabinoid receptors in the brain may trigger undesirable psychoactive effects, scientists have developed synthetic compounds that change the shape of the CB1 receptor and influence how it signals without causing a THC-like high. These compounds, known as allosteric modulators, can either amplify or decrease a receptor’s ability to transmit a signal.

A “positive allosteric modulator” increases the potency and/or efficacy of CB1 receptor activation by anandamide and 2AG (the two main endogenous cannabinoids), thereby boosting the protective effects of the endocannabinoid system.

Scientists at the University of Aberdeen in Scotland have synthesized a positive allosteric modulator of CB1to treat pain and neurological disorders. When researchers at Virginia Commonwealth University tested this experimental drug (“ZCZ011”) on mice, it reduced inflammatory pain by magnifying the CB1 receptor’s response to anandamide.

But allosteric effects are rarely consistent across species, which significantly impedes drug development in this area.4

8. Inhibitors of endocannabinoid metabolizing enzymes

Medical scientists are experimenting with synthetic designer drugs to enhance endocannabinoid tone without binding directly (or allosterically) to cannabinoid receptors.

Pharmacological augmentation of endocannabinoid signaling can be achieved by inhibiting fatty acid amide hydrolase (FAAH) and/or monoglycerol lipase (MAGL), the catabolic enzymes that break down the brain’s own marijuana-like molecules, anandamide and 2AG, respectively.

Simply put, less FAAH and MAGL means more anandamide and 2AG, resulting in greater cannabinoid receptor activity throughout the body. Drugs that suppress endocannabinoid-metabolizing enzymes indirectly boost cannabinoid receptor signaling, causing a natural high without the vivid psychoactive effects associated with synthetic and plant-based CB1 agonists.

Preclinical research suggests that indirect modulation of endocannabinoid signaling could become a treatment option for various inflammatory conditions and stress-related disorders. FAAH and MAGLinhibition have been shown to ease pain, anxiety, colitis, hypertension, opiate withdrawal, diarrhea and arthritis in animal models.

While drug developers investigate synthetic FAAH-inhibitors (such as URB597) and MAGL-inhibitors (such as JZL 184), one need look no further than the kitchen spice rack for phytonutrients that regulate endocannabinoid tone by inhibiting the same catabolic enzymes. Nutmeg, one of many culinary spices that interact with the endocannabinoid system, inhibits the breakdown of both anandamide and 2AG, the brain’s own marijuana.

9. Endocannabinoid reuptake inhibitors

Another way to augment endocannabinoid tone entails delaying the reuptake of anandamide and 2AG. Scientists have synthesized reuptake inhibitors (such as AM404) that target transport molecules known as fatty acid binding proteins. These membrane-penetrating fatty acid binding proteins facilitate the intracellular transport and reuptake of endogenous cannabinoids.

By blocking access to these critical transport molecules, synthetic reuptake inhibitors increase endocannabinoid levels in the brain’s synapses. This results in heightened cannabinoid receptor 

signaling and endocannabinoid-induced protective effects.

THC and CBD also inhibit endocannabinoid reuptake. Enhancing endocannabinoid tone via reuptake inhibition may be a key mechanism whereby plant cannabinoids confer protective effects against seizures and neurodegeneration, as well as many other health benefits.

Fool’s gold?

Despite repeated setbacks, the possibility of healing without the high persists as an idée fixe among cannabinoid scientists and pharmaceutical researchers.

The lack of success with selective CB2 agonists, peripherally restricted CB1 agonists, allosteric modulators, CB1 antagonists and other non-euphoric cannabinoids underscores the challenges and limitations of synthetic, monomolecular medicine that targets a single protein receptor while forsaking whole plant synergies.

Synthetic CBD analogs are also in development. By tweaking the mother molecule and removing, adding or editing a molecular side chain, pharmaceutical researchers hope to create a marketable compound that is more potent and more effective than botanical CBD.

But a CBD isolate is not inherently superior to a whole plant CBD-rich extract. Preclinical studies that compare the efficacy of single-molecule CBD and full spectrum CBD-rich oil concentrates indicate that CBDsolo is effective only at precise, high doses – whereas whole plant CBD-rich extracts have a much wider and safer therapeutic window and are effective at significantly lower doses. Problematic drug interactions are also much likelier with high dose single-molecule CBD.

Regulatory policy should not privilege single-molecule meds over full spectrum cannabis remedies. Patients are best served by having access to a wide range of cannabinoid-based therapeutic options, including artisanal whole plant preparations and synthetic isolates, if and when they become available.

Martin A. Lee is the director of Project CBD and the author of Smoke Signals: A Social History of Marijuana – Medical, Recreational and Scientific.


  1. Only four cannabis compounds bind directly to either one or both cannabinoid receptors. THC activates CB1 and CB2. Cannabinol (CBN), a THC breakdown component, activates the CB1 receptor, though with less potency than THC. Tetrahydracannabivarin (THCV), the propyl variant of THC, binds to both cannabinoid receptors, activating CB2 while blocking CB1. And beta caryophyllene, an aromatic terpene found in many cannabis strains, green leafy vegetables, and common kitchen spices, activates CB2. Other cannabinoids, including CBD, interact with the endocannabinoid system indirectly without binding like lock and key to a cannabinoid receptor.
  2. Developed as a research tool to study that endocannabinoid system, JWH-018 is a synthetic cannabinoid compound that activates the CB1 receptor but not CB2. After the formula for this potent CB1 agonist was published in the scientific literature, JWH-018 surfaced as a street drug known as “Spice” or “K2.” Media accounts typically mischaracterize Spice as “synthetic marijuana.”
  3. U.S. government scientists have not given up entirely on Rimonabant. The fact that this compound blocks the euphoric effects of cannabis is a big plus to the National Institute on Drug Abuse, which has sponsored research on utilizing CB1 blockers to treat various addictions, including “cannabis dependence.”
  4. Canadian scientists have identified CBD as a “negative allosteric modulator” of the CB1 receptor based on in vitro research. This means that CBD, when administered in combination with THC, will alter the shape of the CB1 receptor in a way that weakens its binding affinity for THC. As a negative allosteric modulator of CB1, CBD lowers the ceiling on THC’s psychoactivity, which might be why people don’t feel as high when using CBD-rich cannabis as compared to a THC-infused product.

• Han S, Thatte J, Buzard DJ, Jones RM. Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. J Med Chem. 2013 Nov 14;56(21):8224-56. PubMed PMID: 23865723.
• Ignatowska-Jankowska BM, Baillie GL, Kinsey S, Crowe M, Ghosh S, et al. A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects. Neuropsychopharmacology. 2015 Dec;40(13):2948-59. PubMed PMID: 26052038; PubMed Central PMCID: PMC4864630.
• Mitjavila J, Yin D, Kulkarni PM, Zanato C, Thakur GA, et al. Enantiomer-specific positive allosteric modulation of CB<sub>1</sub> signaling in autaptic hippocampal neurons. Pharmacol Res. 2017 Nov 20;PubMed PMID: 29158048.
• O’Hearn S, Diaz P, Wan BA, DeAngelis C, Lao N, et al. Modulating the endocannabinoid pathway as treatment for peripheral neuropathic pain: a selected review of preclinical studies. Ann Palliat Med. 2017 Aug 31;PubMed PMID: 29156899.
• Pertwee RG, Gibson TM, Stevenson LA, Ross RA, Banner WK, et al. O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. Br J Pharmacol. 2000 Apr;129(8):1577-84. PubMed PMID: 10780961; PubMed Central PMCID: PMC1572002.
• Schindler CW, Scherma M, Redhi GH, Vadivel SK, Makriyannis A, et al. Self-administration of the anandamide transport inhibitor AM404 by squirrel monkeys. Psychopharmacology (Berl). 2016 May;233(10):1867-77. PubMed PMID: 26803499; NIHMSID: NIHMS754451; PubMed Central PMCID: PMC4846479.
• Wasilewski A, Misicka A, Sacharczuk M, Fichna J. Modulation of the endocannabinoid system by the fatty acid amide hydrolase, monoacylglycerol and diacylglycerol lipase inhibitors as an attractive target for secretory diarrhoea therapy. J Physiol Pharmacol. 2017 Aug;68(4):591-596. PubMed PMID: 29151076.
• Yu XH, Cao CQ, Martino G, Puma C, Morinville A, et al. A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain. Pain. 2010 Nov;151(2):337-44. PubMed PMID: 20696525.</

 Related Stories
Categories: News Feeds

Sessions Wrong About Drugged Driving

Alternet - Fri, 12/15/2017 - 11:59
The attorney general claimed there were more traffic deaths from drugs than alcohol last year. But the reports he cited don't back him up.



Sessions Wrong About Drugged Driving

By Vanessa Schipani – Attorney General Jeff Sessions claimed that more car accidents were "caused" by drugs than alcohol for the first time in 2016. ... difficult to prove a person is under the influence of drugs than alcohol while driving. Unlike alcohol, testing positive for a drug - marijuana in particular - doesn't prove intoxication. Marijuana can ...

/* >

 Related Stories
Categories: News Feeds

Cautious Texas Among Last States to OK Medical Marijuana - Leafly

Google - Cannabis - Fri, 12/15/2017 - 11:58


Cautious Texas Among Last States to OK Medical Marijuana
MANCHACA, Texas (AP) — When California rings in the new year with the sale of recreational pot for the first time, Texas will be tiptoeing into its own marijuana milestone: a medical cannabis program so restrictive that doubts swirl over who will even ...

and more »
Categories: News Feeds

Teen Drug Use Reaches a 43-Year Low, With the Exception of Marijuana - Fortune

Google - Cannabis - Fri, 12/15/2017 - 11:38


Teen Drug Use Reaches a 43-Year Low, With the Exception of Marijuana
Teens today are using fewer drugs than the age group has used over the the past 43 years, with one clear exception: marijuana. A recent University of Michigan study found that one in 10 high school seniors say they've vaped marijuana in the past year ...
Overall teen drug use is down, but marijuana and vaping are upChicago Tribune
National study: Adolescent marijuana use edges
Overall teen drug use stable, but marijuana edging up, survey findsCNN
New York Times -NPR -BBC News -National Institute on Drug Abuse
all 110 news articles »
Categories: News Feeds

Compound in Marijuana Appears Safe and Nonaddictive, WHO Says - Live Science

Google - Cannabis - Fri, 12/15/2017 - 11:23

Live Science

Compound in Marijuana Appears Safe and Nonaddictive, WHO Says
Live Science
A compound in marijuana appears to be relatively safe and nonaddictive, according to a new report from the World Health Organization (WHO). In an initial review of existing research, the WHO found that the compound, called cannabidiol or CBD, is ...
Cannabis extract could provide 'new class of treatment' for psychosisThe Independent
World Health Organization clashes with DEA on marijuana compound CBDArs Technica
Cannabis ingredient holds promise as antipsychotic medicineReuters
The Sun -Daily Mail -BuzzFeed News -Newsweek
all 98 news articles »
Categories: News Feeds

Bitcoin offers the cannabis industry an alternative to banks - CNBC

Google - Cannabis - Fri, 12/15/2017 - 08:01


Bitcoin offers the cannabis industry an alternative to banks
Technology companies like SinglePoint and POSaBIT are working to generate a payment method for dispensaries and consumers using bitcoin. In recent years, some cryptocurrencies have cropped up specifically for cannabis transactions, like PotCoin and ...

Categories: News Feeds

Cannabis extract could provide 'new class of treatment' for psychosis - The Independent

Google - Cannabis - Fri, 12/15/2017 - 02:18

The Independent

Cannabis extract could provide 'new class of treatment' for psychosis
The Independent
A key component of medical marijuana could provide an “entirely new” type of treatment for mental health patients suffering with hallucinations and delusions. The first clinical trial exploring the effects of cannabidiol (CBD), one of the major ...
Cannabis ingredient holds promise as antipsychotic medicineReuters
Medical marijuana compound non-addictive, should not be scheduled drug - WHORT
How (the Right Strain of) Weed Can Help Your
Metro -The Sun -teleSUR English
all 66 news articles »
Categories: News Feeds